Retour
Prix Mirxes Holding Company Limited (02629.HK)
Graphique du cours de l'action 02629.HK
MIRXES-B (02629.HK)
Mirxes Holding Company Limited
HK$41.5
-7.77%
$-3.5
Marché Régulier: Jan 19, 09:46:42 HKT
Pas encore de donnéesFollow-Up Questions
Quels sont les états financiers clés de Mirxes Holding Company Limited ?
Quels sont les ratios financiers clés pour 02629.HK ?
Comment les revenus de Mirxes Holding Company Limited sont-ils répartis par segment ou géographie ?
Mirxes Holding Company Limited est-elle rentable ?
Mirxes Holding Company Limited a-t-elle des passifs ?
Combien d'actions en circulation Mirxes Holding Company Limited a-t-elle ?
Statistiques clés
Clôture préc.
$44.46
Prix d'ouverture
$45
Plage de la journée
$41.12 - $45
Plage de 52 semaines
$27.05 - $77.3
Volume
450.7K
Volume moyen
748.9K
BPA (TTM)
-2.15
Rendement en dividend
--
Capitalisation boursière
$11.4B
Qu’est-ce que MIRXES-B ?
Mirxes Holding Co., Ltd. operates as an investment holding company. The company employs 347 full-time employees The company went IPO on 2025-05-23. The company develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. The company offers complete COVID-19 testing solutions.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved